A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 690, Issue 1-2, 2010, Pages 12-23

  Kim, Jiyoung ^a   Cha, Young Nam ^c   Surh, Young Joon ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

^c Inha University School of Medicine   (South Korea)

Author keywords

Antioxidant response element; Heme oxygenase 1; Inflammation; NF B; Nrf2; Redox signaling

Indexed keywords

ANTIINFLAMMATORY AGENT; BENZYL ISOTHIOCYANATE; CELL ADHESION MOLECULE; CHEMOKINE; CURCUMIN; CYCLOOXYGENASE 2; DITHIOLETHIONE; EPICATECHIN GALLATE; HEME OXYGENASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN J2; RESVERATROL; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CELL PROTECTION; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM INFLAMMATION; DNA FLANKING REGION; ELECTROPHILICITY; EMPHYSEMA; ENCEPHALITIS; ENZYME INHIBITION; GASTRITIS; HUMAN; IMMUNOREACTIVITY; INFLAMMATION; MOLECULAR INTERACTION; NEPHRITIS; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN INJURY; UPREGULATION;

ANTIOXIDANTS; AUTOIMMUNE DISEASES; GENE EXPRESSION REGULATION; HEME OXYGENASE (DECYCLIZING); HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; OXIDATIVE STRESS; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION;

EID: 77955279350     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2009.09.007     Document Type: Review

References (132)

1. Lee J.M., Johnson J.A. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J. Biochem. Mol. Biol. 2004, 37:139-143.
2. Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47:89-116.
3. Sporn M.B., Liby K.T. Cancer chemoprevention: scientific promise, clinical uncertainty. Nat. Clin. Pract. Oncol. 2005, 2:518-525.
4. Braun S., Hanselmann C., Gassmann M.G., auf dem Keller U., Born-Berclaz C., Chan K., Kan Y.W., Werner S. Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol. Cell. Biol. 2002, 22:5492-5505.
5. Arisawa T., Tahara T., Shibata T., Nagasaka M., Nakamura M., Kamiya Y., Fujita H., Hasegawa S., Takagi T., Wang F.Y., Hirata I., Nakano H. The relationship between Helicobacter pylori infection and promoter polymorphism of the Nrf2 gene in chronic gastritis. Int. J. Mol. Med. 2007, 19:143-148.
6. Chen X.L., Dodd G., Thomas S., Zhang X., Wasserman M.A., Rovin B.H., Kunsch C. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H1862-1870.
7. Chen X.L., Varner S.E., Rao A.S., Grey J.Y., Thomas S., Cook C.K., Wasserman M.A., Medford R.M., Jaiswal A.K., Kunsch C. Laminar flow induction of antioxidant response element-mediated genes in endothelial cells. A novel anti-inflammatory mechanism. J. Biol. Chem. 2003, 278:703-711.
8. Cho H.Y., Jedlicka A.E., Reddy S.P., Kensler T.W., Yamamoto M., Zhang L.Y., Kleeberger S.R. Role of NRF2 in protection against hyperoxic lung injury in mice. Am. J. Respir. Cell Mol. Biol. 2002, 26:175-182.
9. Cho H.Y., Reddy S.P., Yamamoto M., Kleeberger S.R. The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J. 2004, 18:1258-1260.
10. Ma Q., Battelli L., Hubbs A.F. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am. J. Pathol. 2006, 168:1960-1974.
11. Kwak M.K., Wakabayashi N., Itoh K., Motohashi H., Yamamoto M., Kensler T.W. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem. 2003, 278:8135-8145.
12. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999, 13:76-86.
13. Furukawa M., Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol. Cell. Biol. 2005, 25:162-171.
14. Kobayashi A., Kang M.I., Okawa H., Ohtsuji M., Zenke Y., Chiba T., Igarashi K., Yamamoto M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 2004, 24:7130-7139.
15. Itoh K., Igarashi K., Hayashi N., Nishizawa M., Yamamoto M. Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Mol. Cell. Biol. 1995, 15:4184-4193.
16. Dinkova-Kostova A.T., Holtzclaw W.D., Kensler T.W. The role of Keap1 in cellular protective responses. Chem. Res. Toxicol. 2005, 18:1779-1791.
17. Wakabayashi N., Dinkova-Kostova A.T., Holtzclaw W.D., Kang M.I., Kobayashi A., Yamamoto M., Kensler T.W., Talalay P. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:2040-2045.
18. Dinkova-Kostova A.T., Holtzclaw W.D., Cole R.N., Itoh K., Wakabayashi N., Katoh Y., Yamamoto M., Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11908-11913.
19. Hong F., Freeman M.L., Liebler D.C. Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem. Res. Toxicol. 2005, 18:1917-1926.
20. Hong F., Sekhar K.R., Freeman M.L., Liebler D.C. Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. J. Biol. Chem. 2005, 280:31768-31775.
21. Keum Y.S., Owuor E.D., Kim B.R., Hu R., Kong A.N. Involvement of Nrf2 and JNK1 in the activation of antioxidant responsive element (ARE) by chemopreventive agent phenethyl isothiocyanate (PEITC). Pharm. Res. 2003, 20:1351-1356.
22. Venugopal R., Jaiswal A.K. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:14960-14965.
23. Levonen A.L., Inkala M., Heikura T., Jauhiainen S., Jyrkkanen H.K., Kansanen E., Maatta K., Romppanen E., Turunen P., Rutanen J., Yla-Herttuala S. Nrf2 gene transfer induces antioxidant enzymes and suppresses smooth muscle cell growth in vitro and reduces oxidative stress in rabbit aorta in vivo. Arterioscler. Thromb. Vasc. Biol. 2007, 27:741-747.
24. Sun X., Erb H., Murphy T.H. Coordinate regulation of glutathione metabolism in astrocytes by Nrf2. Biochem. Biophys. Res. Commun. 2005, 326:371-377.
25. Kraft A.D., Johnson D.A., Johnson J.A. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J. Neurosci. 2004, 24:1101-1112.
26. Purdom-Dickinson S.E., Lin Y., Dedek M., Morrissy S., Johnson J., Chen Q.M. Induction of antioxidant and detoxification response by oxidants in cardiomyocytes: evidence from gene expression profiling and activation of Nrf2 transcription factor. J. Mol. Cell. Cardiol. 2007, 42:159-176.
27. Alam J., Stewart D., Touchard C., Boinapally S., Choi A.M., Cook J.L. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J. Biol. Chem 1999, 274:26071-26078.
28. Srisook K., Kim C., Cha Y.N. Molecular mechanisms involved in enhancing HO-1 expression: de-repression by heme and activation by Nrf2, the " one-two" punch. Antioxid. Redox Signal. 2005, 7:1674-1687.
29. Rushworth S.A., O'Connell M.A. Haem oxygenase-1 in inflammation. Biochem. Soc. Trans. 2004, 32:1093-1094.
30. He C.H., Gong P., Hu B., Stewart D., Choi M.E., Choi A.M., Alam J. Identification of activating transcription factor 4 (ATF4) as an Nrf2-interacting protein. Implication for heme oxygenase-1 gene regulation. J. Biol. Chem. 2001, 276:20858-20865.
31. Yachie A., Toma T., Mizuno K., Okamoto H., Shimura S., Ohta K., Kasahara Y., Koizumi S. Heme oxygenase-1 production by peripheral blood monocytes during acute inflammatory illnesses of children. Exp. Biol. Med. (Maywood) 2003, 228:550-556.
32. Tamion F., Richard V., Renet S., Thuillez C. Intestinal preconditioning prevents inflammatory response by modulating heme oxygenase-1 expression in endotoxic shock model. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293:G1308-1314.
33. Almolki A., Guenegou A., Golda S., Boyer L., Benallaoua M., Amara N., Bachoual R., Martin C., Rannou F., Lanone S., Dulak J., Burgel P.R., El-Benna J., Leynaert A.B., Aubier M., Boczkowski J. Heme oxygenase-1 prevents airway mucus hypersecretion induced by cigarette smoke in rodents and humans. Am. J. Pathol. 2008, 173:981-992.
34. Lin C.C., Liu X.M., Peyton K., Wang H., Yang W.C., Lin S.J., Durante W. Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1. Arterioscler. Thromb. Vasc. Biol. 2008, 28:739-745.
35. Horvath K., Varga C., Berko A., Posa A., Laszlo F., Whittle B.J. The involvement of heme oxygenase-1 activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis. Eur. J. Pharmacol. 2008, 581:315-323.
36. Syapin P.J. Regulation of haeme oxygenase-1 for treatment of neuroinflammation and brain disorders. Br. J. Pharmacol. 2008, 155:623-640.
37. Cuadrado A., Rojo A.I. Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections. Curr. Pharm. Des. 2008, 14:429-442.
38. Pae H.O., Ae Ha Y., Chai K.Y., Chung H.T. Heme oxygenase-1 attenuates contact hypersensitivity induced by 2,4-dinitrofluorobenzene in mice. Immunopharmacol. Immunotoxicol. 2008, 30:207-216.
39. Patil K., Bellner L., Cullaro G., Gotlinger K.H., Dunn M.W., Schwartzman M.L. Heme oxygenase-1 induction attenuates corneal inflammation and accelerates wound healing after epithelial injury. Invest. Ophthalmol. Vis. Sci. 2008, 49:3379-3386.
40. Sun B., Zou X., Chen Y., Zhang P., Shi G. Preconditioning of carbon monoxide releasing molecule-derived CO attenuates LPS-induced activation of HUVEC. Int. J. Biol. Sci. 2008, 4:270-278.
41. Sun B.W., Sun Y., Sun Z.W., Chen X. CO liberated from CORM-2 modulates the inflammatory response in the liver of thermally injured mice. World J. Gastroenterol. 2008, 14:547-553.
42. Ferrandiz M.L., Maicas N., Garcia-Arnandis I., Terencio M.C., Motterlini R., Devesa I., Joosten L.A., van den Berg W.B., Alcaraz M.J. Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis. Ann. Rheum. Dis. 2008, 67:1211-1217.
43. Chung S.W., Liu X., Macias A.A., Baron R.M., Perrella M.A. Heme oxygenase-1-derived carbon monoxide enhances the host defense response to microbial sepsis in mice. J. Clin. Invest. 2008, 118:239-247.
44. Freitas A., Alves-Filho J.C., Secco D.D., Neto A.F., Ferreira S.H., Barja-Fidalgo C., Cunha F.Q. Heme oxygenase/carbon monoxide-biliverdin pathway down regulates neutrophil rolling, adhesion and migration in acute inflammation. Br. J. Pharmacol. 2006, 149:345-354.
45. Overhaus M., Moore B.A., Barbato J.E., Behrendt F.F., Doering J.G., Bauer A.J. Biliverdin protects against polymicrobial sepsis by modulating inflammatory mediators. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G695-703.
46. Sarady-Andrews J.K., Liu F., Gallo D., Nakao A., Overhaus M., Ollinger R., Choi A.M., Otterbein L.E. Biliverdin administration protects against endotoxin-induced acute lung injury in rats. Am. J. Physiol Lung Cell. Mol. Physiol. 2005, 289:L1131-1137.
47. Berberat P.O., YI A.R., Yamashita K., Warny M.M., Csizmadia E., Robson S.C., Bach F.H. Heme oxygenase-1-generated biliverdin ameliorates experimental murine colitis. Inflamm. Bowel Dis. 2005, 11:350-359.
48. Liu Y., Zhu B., Wang X., Luo L., Li P., Paty D.W., Cynader M.S. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J. Neuroimmunol. 2003, 139:27-35.
49. Sawada K., Ohnishi K., Kosaka T., Chikano S., Egashira A., Okui M., Shintani S., Wada M., Nakasho K., Shimoyama T. Exacerbated autoimmune hepatitis successfully treated with leukocytapheresis and bilirubin adsorption therapy. J. Gastroenterol. 1997, 32:689-695.
50. Kadl A., Pontiller J., Exner M., Leitinger N. Single bolus injection of bilirubin improves the clinical outcome in a mouse model of endotoxemia. Shock 2007, 28:582-588.
51. Wang W.W., Smith D.L., Zucker S.D. Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats. Hepatology 2004, 40:424-433.
52. Lanone S., Bloc S., Foresti R., Almolki A., Taille C., Callebert J., Conti M., Goven D., Aubier M., Dureuil B., El-Benna J., Motterlini R., Boczkowski J. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J. 2005, 19:1890-1892.
53. Keshavan P., Deem T.L., Schwemberger S.J., Babcock G.F., Cook-Mills J.M., Zucker S.D. Unconjugated bilirubin inhibits VCAM-1-mediated transendothelial leukocyte migration. J. Immunol. 2005, 174:3709-3718.
54. Kawamura K., Ishikawa K., Wada Y., Kimura S., Matsumoto H., Kohro T., Itabe H., Kodama T., Maruyama Y. Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler. Thromb. Vasc. Biol. 2005, 25:155-160.
55. Thimmulappa R.K., Lee H., Rangasamy T., Reddy S.P., Yamamoto M., Kensler T.W., Biswal S. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J. Clin. Invest. 2006, 116:984-995.
56. Khor T.O., Huang M.T., Kwon K.H., Chan J.Y., Reddy B.S., Kong A.N. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res. 2006, 66:11580-11584.
57. Osburn W.O., Karim B., Dolan P.M., Liu G., Yamamoto M., Huso D.L., Kensler T.W. Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int. J. Cancer. 2007, 121:1883-1891.
58. Bondeson J., Sundler R. Auranofin inhibits the induction of interleukin 1 beta and tumor necrosis factor alpha mRNA in macrophages. Biochem. Pharmacol. 1995, 50:1753-1759.
59. Yoshida S., Kato T., Sakurada S., Kurono C., Yang J.P., Matsui N., Soji T., Okamoto T. Inhibition of IL-6 and IL-8 induction from cultured rheumatoid synovial fibroblasts by treatment with aurothioglucose. Int. Immunol. 1999, 11:151-158.
60. Nathan C. Points of control in inflammation. Nature 2002, 420:846-852.
61. Pae H.O., Oh G.S., Lee B.S., Rim J.S., Kim Y.M., Chung H.T. 3-Hydroxyanthranilic acid, one of L-tryptophan metabolites, inhibits monocyte chemoattractant protein-1 secretion and vascular cell adhesion molecule-1 expression via heme oxygenase-1 induction in human umbilical vein endothelial cells. Atherosclerosis 2006, 187:274-284.
62. Lee S.H., Sohn D.H., Jin X.Y., Kim S.W., Choi S.C., Seo G.S. 2',4',6'-Tris(methoxymethoxy) chalcone protects against trinitrobenzene sulfonic acid-induced colitis and blocks tumor necrosis factor-alpha-induced intestinal epithelial inflammation via heme oxygenase 1-dependent and independent pathways. Biochem. Pharmacol. 2007, 74:870-880.
63. Ho F.M., Kang H.C., Lee S.T., Chao Y., Chen Y.C., Huang L.J., Lin W.W. The anti-inflammatory actions of LCY-2-CHO, a carbazole analogue, in vascular smooth muscle cells. Biochem. Pharmacol. 2007, 74:298-308.
64. Yang L., Froio R.M., Sciuto T.E., Dvorak A.M., Alon R., Luscinskas F.W. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood 2005, 106:584-592.
65. Banning A., Brigelius-Flohe R. NF-kappaB, Nrf2, and HO-1 interplay in redox-regulated VCAM-1 expression. Antioxid. Redox Signal. 2005, 7:889-899.
66. Soares M.P., Seldon M.P., Gregoire I.P., Vassilevskaia T., Berberat P.O., Yu J., Tsui T.Y., Bach F.H. Heme oxygenase-1 modulates the expression of adhesion molecules associated with endothelial cell activation. J. Immunol. 2004, 172:3553-3563.
67. Kim B.C., Jeon W.K., Hong H.Y., Jeon K.B., Hahn J.H., Kim Y.M., Numazawa S., Yosida T., Park E.H., Lim C.J. The anti-inflammatory activity of Phellinus linteus (Berk. & M.A. Curt.) is mediated through the PKCdelta/Nrf2/ARE signaling to up-regulation of heme oxygenase-1. J. Ethnopharmacol. 2007, 113:240-247.
68. Williams C.S., Mann M., DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18:7908-7916.
69. Steele V.E., Hawk E.T., Viner J.L., Lubet R.A. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat. Res. 2003, 523-524:137-144.
70. Kundu J.K., Shin Y.K., Surh Y.J. Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-κB and AP-1 as prime targets. Biochem. Pharmacol. 2006, 72:1506-1515.
71. Healy Z.R., Lee N.H., Gao X., Goldring M.B., Talalay P., Kensler T.W., Konstantopoulos K. Divergent responses of chondrocytes and endothelial cells to shear stress: cross-talk among COX-2, the phase 2 response, and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:14010-14015.
72. Karuri A.R., Huang Y., Bodreddigari S., Sutter C.H., Roebuck B.D., Kensler T.W., Sutter T.R. 3H-1,2-dithiole-3-thione targets nuclear factor kB to block expression of inducible nitric-oxide synthase, prevents hypotension, and improves survival in endotoxemic rats. J. Pharmacol. Exp. Ther. 2006, 317:61-67.
73. Chen X.L., Kunsch C. Induction of cytoprotective genes through Nrf2/antioxidant response element pathway: a new therapeutic approach for the treatment of inflammatory diseases. Curr. Pharm. Des. 2004, 10:879-891.
74. Perkins N.D. The Rel/NF-kappa B family: friend and foe. Trends Biochem. Sci. 2000, 25:434-440.
75. Schreck R., Rieber P., Baeuerle P.A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J. 1991, 10:2247-2258.
76. Sozzani S., Bosisio D., Mantovani A., Ghezzi P. Linking stress, oxidation and the chemokine system. Eur. J. Immunol. 2005, 35:3095-3098.
77. Ardite E., Barbera J.A., Roca J., Fernandez-Checa J.C. Glutathione depletion impairs myogenic differentiation of murine skeletal muscle C2C12 cells through sustained NF-κB activation. Am. J. Pathol. 2004, 165:719-728.
78. Cho H.Y., Imani F., Miller-Degraff L., Walters D., Melendi G.A., Yamamoto M., Polack F.P., Kleeberger S.R. Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus (RSV) disease. Am. J. Respir. Crit. Care Med. 2008, 179:138-150.
79. Heiss E., Herhaus C., Klimo K., Bartsch H., Gerhauser C. Nuclear factor κB is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J. Biol. Chem. 2001, 276:32008-32015.
80. Na H.-K., Surh Y.-J. Transcriptional regulation via cysteine thiol modification: a novel molecular strategy for chemoprevention and cytoprotection. Mol. Carcinog. 2006, 45:368-380.
81. Funakoshi-Tago M., Tago K., Sonoda Y., Tominaga S., Kasahara T. TRAF6 and C-SRC induce synergistic AP-1 activation via PI3-kinase-AKT-JNK pathway. Eur. J. Biochem. 2003, 270:1257-1268.
82. Manna S.K., Mukhopadhyay A., Aggarwal B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 2000, 164:6509-6519.
83. Gopalakrishnan A., Tony Kong A.N. Anticarcinogenesis by dietary phytochemicals: cytoprotection by Nrf2 in normal cells and cytotoxicity by modulation of transcription factors NF-kappa B and AP-1 in abnormal cancer cells. Food Chem. Toxicol. 2008, 46:1257-1270.
84. Zhu M., Zhang Y., Cooper S., Sikorski E., Rohwer J., Bowden G.T. Phase II enzyme inducer, sulforaphane, inhibits UVB-induced AP-1 activation in human keratinocytes by a novel mechanism. Mol. Carcinog. 2004, 41:179-186.
85. 2 as a potential endogenous regulator of redox-sensitive transcription factors. Biochem. Pharmacol. 2006, 72:1516-1528.
86. O'Neill L.A. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat. Rev. Drug Discov. 2006, 5:549-563.
87. Van Eldik L.J., Thompson W.L., Ralay Ranaivo H., Behanna H.A., Martin D. Watterson Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int. Rev. Neurobiol. 2007, 82:277-296.
88. Lee J.M., Chan K., Kan Y.W., Johnson J.A. Targeted disruption of Nrf2 causes regenerative immune-mediated hemolytic anemia. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:9751-9756.
89. Yoh K., Itoh K., Enomoto A., Hirayama A., Yamaguchi N., Kobayashi M., Morito N., Koyama A., Yamamoto M., Takahashi S. Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int. 2001, 60:1343-1353.
90. Rangasamy T., Guo J., Mitzner W.A., Roman J., Singh A., Fryer A.D., Yamamoto M., Kensler T.W., Tuder R.M., Georas S.N., Biswal S. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J. Exp. Med. 2005, 202:47-59.
91. Kataoka K., Handa H., Nishizawa M. Induction of cellular antioxidative stress genes through heterodimeric transcription factor Nrf2/small Maf by antirheumatic gold(I) compounds. J. Biol. Chem. 2001, 276:34074-34081.
92. Abraham E. Neutrophils and acute lung injury. Crit. Care Med. 2003, 31:S195-199.
93. Tomashefski J.F. Pulmonary pathology of acute respiratory distress syndrome. Clin. Chest Med. 2000, 21:435-466.
94. Ware L.B., Matthay M.A. The acute respiratory distress syndrome. N. Engl. J. Med. 2000, 342:1334-1349.
95. 2 and Nrf2 pathways in protection against acute lung injury. Am. J. Respir. Crit. Care Med. 2005, 171:1260-1266.
96. Cho H.Y., Jedlicka A.E., Reddy S.P., Zhang L.Y., Kensler T.W., Kleeberger S.R. Linkage analysis of susceptibility to hyperoxia. Nrf2 is a candidate gene. Am. J. Respir. Cell. Mol. Biol. 2002, 26:42-51.
97. Marzec J.M., Christie J.D., Reddy S.P., Jedlicka A.E., Vuong H., Lanken P.N., Aplenc R., Yamamoto T., Yamamoto M., Cho H.Y., Kleeberger S.R. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J. 2007, 21:2237-2246.
98. Elias J.A., Lee C.G., Zheng T., Ma B., Homer R.J., Zhu Z. New insights into the pathogenesis of asthma. J. Clin. Invest. 2003, 111:291-297.
99. Renauld J.C. New insights into the role of cytokines in asthma. J. Clin. Pathol. 2001, 54:577-589.
100. Roth M., Black J.L. Transcription factors in asthma: are transcription factors a new target for asthma therapy?. Curr. Drug Targets 2006, 7:589-595.
101. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 1999, 17:255-281.
102. Li N., Nel A.E. Role of the Nrf2-mediated signaling pathway as a negative regulator of inflammation: implications for the impact of particulate pollutants on asthma. Antioxid. Redox Signal. 2006, 8:88-98.
103. Powell C.V., Nash A.A., Powers H.J., Primhak R.A. Antioxidant status in asthma. Pediatr. Pulmonol. 1994, 18:34-38.
104. Fryer A.A., Bianco A., Hepple M., Jones P.W., Strange R.C., Spiteri M.A. Polymorphism at the glutathione S-transferase GSTP1 locus. A new marker for bronchial hyperresponsiveness and asthma. Am. J. Respir. Crit. Care Med. 2000, 161:1437-1442.
105. Nagai A., Inano H., Matsuba K., Thurlbeck W.M. Scanning electronmicroscopic morphometry of emphysema in humans. Am. J. Respir. Crit. Care Med. 1994, 150:1411-1415.
106. Snider G.L. Emphysema: the first two centuries--and beyond. A historical overview, with suggestions for future research: Part 1. Am. Rev. Respir. Dis. 1992, 146:1334-1344.
107. Mahadeva R., Shapiro S.D. Chronic obstructive pulmonary disease * 3. Experimental animal models of pulmonary emphysema. Thorax 2002, 57:908-914.
108. Barnes P.J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 2000, 343:269-280.
109. Barnes P.J. New concepts in chronic obstructive pulmonary disease. Annu. Rev. Med. 2003, 54:113-129.
110. Repine J.E., Bast A., Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am. J. Respir. Crit. Care Med. 1997, 156:341-357.
111. Iizuka T., Ishii Y., Itoh K., Kiwamoto T., Kimura T., Matsuno Y., Morishima Y., Hegab A.E., Homma S., Nomura A., Sakamoto T., Shimura M., Yoshida A., Yamamoto M., Sekizawa K. Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells 2005, 10:1113-1125.
112. Ishii Y., Itoh K., Morishima Y., Kimura T., Kiwamoto T., Iizuka T., Hegab A.E., Hosoya T., Nomura A., Sakamoto T., Yamamoto M., Sekizawa K. Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J. Immunol. 2005, 175:6968-6975.
113. Rangasamy T., Cho C.Y., Thimmulappa R.K., Zhen L., Srisuma S.S., Kensler T.W., Yamamoto M., Petrache I., Tuder R.M., Biswal S. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Invest. 2004, 114:1248-1259.
114. Rahman I. Regulation of glutathione in inflammation and chronic lung diseases. Mutat. Res. 2005, 579:58-80.
115. Aburaya M., Tanaka K., Hoshino T., Tsutsumi S., Suzuki K., Makise M., Akagi R., Mizushima T. Heme oxygenase-1 protects gastric mucosal cells against non-steroidal anti-inflammatory drugs. J. Biol. Chem. 2006, 281:33422-33432.
116. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
117. Marui N., Offermann M.K., Swerlick R., Kunsch C., Rosen C.A., Ahmad M., Alexander R.W., Medford R.M. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J. Clin. Invest. 1993, 92:1866-1874.
118. Ishii T., Itoh K., Ruiz E., Leake D.S., Unoki H., Yamamoto M., Mann G.E. Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ. Res. 2004, 94:609-616.
119. Podrez E.A., Poliakov E., Shen Z., Zhang R., Deng Y., Sun M., Finton P.J., Shan L., Febbraio M., Hajjar D.P., Silverstein R.L., Hoff H.F., Salomon R.G., Hazen S.L. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 2002, 277:38517-38523.
120. 2 in human mesangial cells. Kidney Int. 2004, 65:798-810.
121. Asghar M., George L., Lokhandwala M.F. Exercise decreases oxidative stress and inflammation and restores renal dopamine D1 receptor function in old rats. Am. J. Physiol. Renal Physiol. 2007, 293:F914-919.
122. Werner S. Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine Growth Factor Rev. 1998, 9:153-165.
123. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8:57-69.
124. Craft J.M., Watterson D.M., Van Eldik L.J. Neuroinflammation: a potential therapeutic target. Expert Opin. Ther. Targets 2005, 9:887-900.
125. Innamorato N.G., Rojo A.I., Garcia-Yague A.J., Yamamoto M., de Ceballos M.L., Cuadrado A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J. Immunol. 2008, 181:680-689.
126. Calabrese V., Ravagna A., Colombrita C., Scapagnini G., Guagliano E., Calvani M., Butterfield D.A., Giuffrida A.M. Stella Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J. Neurosci. Res. 2005, 79:509-521.
127. Zhao X., Sun G., Zhang J., Strong R., Dash P.K., Kan Y.W., Grotta J.C., Aronowski J. Transcription factor Nrf2 protects the brain from damage produced by intracerebral hemorrhage. Stroke 2007, 38:3280-3286.
128. Wang J., Fields J., Zhao C., Langer J., Thimmulappa R.K., Kensler T.W., Yamamoto M., Biswal S., Dore S. Role of Nrf2 in protection against intracerebral hemorrhage injury in mice. Free Radic. Biol. Med. 2007, 43:408-414.
129. Kraft A.D., Lee J.M., Johnson D.A., Kan Y.W., Johnson J.A. Neuronal sensitivity to kainic acid is dependent on the Nrf2-mediated actions of the antioxidant response element. J. Neurochem. 2006, 98:1852-1865.
130. Hubbs A.F., Benkovic S.A., Miller D.B., O'Callaghan J.P., Battelli L., Schwegler-Berry D., Ma Q. Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2. Am. J. Pathol. 2007, 170:2068-2076.
131. 2-induced apoptosis through Nrf2-mediated upregulation of heme oxygenase-1: potential roles of Akt and ERK1/2. Biochem. Pharmacol. 2008, 76:1577-1589.
132. Koh K., Cha Y., Kim S., Kim J. tBHQ inhibits LPS-induced microglial activation via Nrf2-mediated suppression of p38 phosphorylation. Biochem. Biophys. Res. Commun. 2009, 380:449-453.